Breaks Categories: News

MondayNov 21, 2022 12:50 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Focus on Dementia and Diabetes Featured in New Interview

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, was featured in an interview produced by PCG Digital Holdings LLC and published on NewMediaWire. John Docherty, Lexaria’s president and head of research, discussed the company’s efforts to investigate the potential therapeutic utility of its proprietary DehydraTECH(TM)-CBD against dementia and diabetes, two of the world’s largest public health crises. Lexaria recently demonstrated DehydraTECH-CBD’s exceptional safety and tolerability in a human hypertension study, as well as statistically significant lowering of blood pressure over multiple weeks (something that previous studies by others have failed to evidence). Strong connections exist between…

Continue Reading

MondayNov 21, 2022 11:36 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Schedules Q3 2022 Earnings Call

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that it will host its third quarter 2022 earnings call via webcast at 4:30 p.m. ET on Monday, Nov. 28. During the webcast, Flora management will deliver financial and operational results for the third quarter ended Sept. 30, 2022, and provide updates on the company’s commercial wholesale operations, house of brands and life sciences division strategies. Following the presentation, Flora management will open the call to analysts, media and investors in a Q&A format. Interested parties should visit https://cnw.fm/0ku2U to register for…

Continue Reading

FridayNov 18, 2022 10:43 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has entered into a securities purchase agreement with two healthcare-focused institutional investors. The agreement outlines plans for the issuance and sale of 1,818,185 of INM common shares; the shares will be issued at a purchase price of $3.30 per share or prefunded warrant. In addition, the agreement notes that INM will issue unregistered preferred investment options to the same investors; those options include purchasing up to 3,272,733 additional common shares. According to the announcement, the company anticipates the private placement, which…

Continue Reading

ThursdayNov 17, 2022 11:29 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has named Sarah Li as vice president of accounting and InMed controller; the change will be effective Nov. 20, 2022. Li is replacing Brenda Edwards, who has been serving as interim chief financial officer for the company. Edwards joined InMed in the interim contract role in March after the company’s CFO retired. “We are pleased to announce this promotion of Ms. Li to her new position as VP of Accounting and Controller,” said InMed president and CEO Eric A. Adams in…

Continue Reading

WednesdayNov 16, 2022 1:59 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation to the treatment of neurodegenerative diseases; the new program will focus on two lead analogs to conduct studies using in vivo models to select the most appropriate candidate for clinical studies. The company anticipates that early preclinical…

Continue Reading

MondayNov 14, 2022 12:19 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Partners with 357 Company to Launch Cannabis Division

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is working with the 357 Company to launch 357’s Canna Logistics division. The new division is an expansion beyond 357’s Hemp Logistics segment, which ships federally legal hemp within the United States. According to the announcement, the new division will focus on logistics management and shipping of cannabis and hemp between countries where cannabis has been legalized. 357 is working to expand into international shipping of cannabis, hemp and industrial hemp; the cannabis export/import industry is new and poses significant potential for shipments of…

Continue Reading

MondayNov 14, 2022 12:03 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has reported its financial results for the first quarter of fiscal year 2023, ended Sept. 30, 2022. Highlights of the report included updates on the company’s pharmaceutical development programs, including INM-755 for the treatment of epidermolysis bullosa (“EB”) and INM-088 for the treatment of glaucoma. According to the report, enrollment and patient treatment in the company’s phase 2 clinical trial for INM-755 should be complete by the end of the year while the company continues to conduct key preclinical work including toxicology and GLP studies in…

Continue Reading

ThursdayNov 10, 2022 2:17 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First-Ever Study Exploring Therapeutic Use of DehydraTECH-CBD in Dementia

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is starting a new study program — DEM-A22-1 — on Nov. 15, 2022. The study, a first for Lexaria, will evaluate whether LEXX’s DehydraTECH-processed cannabidiol (“CBD”) may have potential for therapeutic treatment for dementia. According to the announcement, Lexaria has previously shown the efficacy of DehydraTECH-CBD in studies focused on human hypertension; the studies showed no serious side effects. Lexaria is exploring the potential for dementia based on previous clinical studies that have established connections between hypertension and dementia: specifically, that individuals who have high blood pressure are more likely…

Continue Reading

ThursdayNov 10, 2022 1:57 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Reports Majority of Franchise Global Health (TSX.V: FGH) Shareholders Approve Acquisition

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is one step closer to completing its previously announced acquisition of Franchise Global Health (TSX.V: FGH). FLGC announced that holders of more than 73% of the outstanding shares of FGH have agreed to vote their shares in favor of Flora’s acquisition of FGH; the voting will take place during FGH’s special meeting of shareholders, scheduled for Dec. 13, 2022. The completion of the acquisition remains subject to customary closing conditions, including approval of the plan of arrangement by the Supreme Court of British Columbia…

Continue Reading

ThursdayNov 10, 2022 12:08 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that its CEO Eric A. Adams and SVP of Preclinical Research and Development Eric Hsu will present at Tribe Public’s upcoming webinar presentation and Q&A event. Titled “Exploring the Neuroprotective Qualities of Rare Cannabinoids,” the event is scheduled to begin at 8:30 a.m. Pacific Time on Nov. 17, 2022. Interested parties should visit https://cnw.fm/ebyJy to register for and join the complimentary, Zoom webinar-based event. Once registered, participants may begin forwarding their questions for InMed’s management to Tribe Public at…

Continue Reading